Peer Review Findings Published reLead Therapeutic Compound VAL201
And New Launch of Group Website
ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, is pleased to report that European Oncology & Haematology, Volume 8, Issue 1, Spring 2012 has just published a review by independent experts, on ValiRx's lead therapeutic VAL201 and its potentially important role in the treatment of hormone induced refractory prostate cancer.
In this article, an independent review of the current gold standard (docetaxel) and other current and pipeline therapeutics for the treatment of hormone induced refractory prostate cancer, has indicated that ValiRx's drug candidate, VAL201 may have an important role in treating this condition with the potential of significantly reducing side effects commonly associated with treatment.
Currently, VAL201 is undergoing late stage preclinical and toxicology studies to support the regulatory requirements prior to entering clinical trials.
To read the full report, please visit the Group's new and recently re-launched corporate website: www.valirx.com
Dr Satu Vainikka, CEO, commented: "I am delighted with the progress we are seeing in the development of VAL201 and am grateful for the endorsement this review represents. The market for treatments against hormone induced tumour growth and associated conditions is significant and these conditions have significant unmet clinical need."
"I am also delighted to see our new website launched and hope it will aid communication with our investors and all audiences as we approach an exciting new chapter in the Company's development".
ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.
The Company listed on AIM in October 2006 and is creating a portfolio of innovative products through investment in specific development projects. It actively manages projects within this portfolio as a trading company and is not an investment vehicle. The ValiRx business model spreads the risks of life science technology developments by minimising financial exposure and running a set of projects to defined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.
The Company operates through the following divisional companies:
· ValiMedix is the sales and distribution division of ValiRx
· ValiPharma is the therapeutics division with two embedded technologies primarily directed at the treatment of cancers.
· ValiFinn is the biomarkers and diagnostic development of the group. It is actively discovering, developing, and validating functional biomarkers and diagnostics with high specificity and sensitivity from its 5 families of patents and patent applications and related intellectual property held by the group relating to companion diagnostics.
This information is provided by RNS
The company news service from the London Stock Exchange
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.